Neurotrophic Keratitis Treatment Market Report 2026

Neurotrophic Keratitis Treatment Market Overview

• Neurotrophic Keratitis Treatment market size has reached to $1.47 billion in 2025 • Expected to grow to $6.78 billion in 2030 at a compound annual growth rate (CAGR) of 35.8% • Growth Driver: Rising Prevalence Of Eye Diseases Fuels Growth In The Neurotrophic Keratitis Treatment Market • Market Trend: Innovations In Gene-Therapy Eye Drops Enhance Treatment And Reduce Burden In Neurotrophic Keratitis • North America was the largest region in 2025.

What Is Covered Under Neurotrophic Keratitis Treatment Market?

Neurotrophic keratitis treatment refers to a treatment method to cure a rare eye condition caused by damage to the trigeminal nerve, leading to decreased corneal sensation and potential corneal damage. This treatment is used to protect the cornea, promote healing, alleviate symptoms, and prevent further damage. The main types of neurotrophic keratitis treatment are topical antibiotics, recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, keratoplasty, and others. Topical antibiotics refer to antimicrobial medications that are applied directly to the surface of the skin or mucous membranes. It is consumed through a variety of administrations, such as oral, topical, and others for several applications including stage I, stage II, and stage III neurotropic keratitis by various end-users such as hospitals, homecare, specialty clinics, and others.

What Is The Neurotrophic Keratitis Treatment Market Growth Forecast?

The neurotrophic keratitis treatment market size is expected to see exponential growth in the next few years. It will grow to $6.78 billion in 2030 at a compound annual growth rate (CAGR) of 35.8%. The growth in the forecast period can be attributed to advancements in regenerative ophthalmic therapies, increasing approvals of rhNGF-based drugs, growing aging population with nerve degeneration risks, rising investment in rare eye disease research, expanding access to advanced eye care in emerging markets. Major trends in the forecast period include rising adoption of recombinant human nerve growth factor therapies, growing preference for minimally invasive corneal repair procedures, increased focus on early-stage diagnosis and intervention, expansion of homecare-based ophthalmic treatment solutions, advancements in amniotic membrane preservation techniques.

Global Neurotrophic Keratitis Treatment Market Segmentation

1) By Treatment: Topical Antibiotics, Recombinant Human Nerve Growth Factor (rhNGF), Amniotic Membrane Transplantation, Keratoplasty, Other Treatments 2) By Route Of Administration: Oral, Topical, Other Routes Of Administrations 3) By Application: Stage I, Stage II, Stage III 4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Topical Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics 2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution 3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane, Dehydrated Amniotic Membrane 4) By Keratoplasty: Penetrating Keratoplasty, Lamellar Keratoplasty 5) By Other Treatments: Tarsorrhaphy, Therapeutic Contact Lenses

What Is The Driver Of The Neurotrophic Keratitis Treatment Market?

The growing prevalence of eye diseases is expected to propel the growth of the neurotrophic keratitis treatment market going forward. Eye diseases include a wide range of conditions that affect the structure and function of the eyes, leading to impaired vision or blindness. The rise in eye disease prevalence is driven by factors such as population aging, lifestyle changes, and the increasing incidence of chronic conditions like diabetes. Neurotrophic keratitis treatment supports eye health by improving corneal sensation, promoting healing, preventing infection, and alleviating pain. For instance, in August 2023, according to the World Health Organization (WHO), a Switzerland-based United Nations agency, global estimates indicate that 2.2 billion people have near or distance vision impairment, including 1 billion cases that are preventable or untreated, while refractive errors and cataracts remain the leading global causes of vision loss, and only 36% of individuals with refractive-error–related distance impairment and just 17% of those with cataract-related impairment have received appropriate care. Therefore, the growing prevalence of eye diseases is driving the growth of the neurotrophic keratitis treatment industry.

Key Players In The Global Neurotrophic Keratitis Treatment Market

Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Johnson & Johnson, Allergan Inc, Alcon Inc, Bausch Health Companies Inc, Bausch & Lomb Inc, CooperVision Inc, Santen Pharmaceutical Co Ltd, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc, Laboratoires Thea SAS, ReGenTree LLC, Contacare Ophthalmic Private Limited, Neuroptika Inc, Surgitech Innovation Private Limited, Aerie Pharmaceuticals Inc, RegeneRx Biopharmaceuticals Inc, Noveome Biotherapeutics Inc, Oyster Point Pharma, Claris Biotherapeutics, Recordati Rare Diseases, Mitotech SA, Kala Pharmaceuticals, Oxurion NV

Global Neurotrophic Keratitis Treatment Market Trends and Insights

Major companies operating in the neurotrophic keratitis market are focusing on developing advanced gene-therapy solutions, such as redosable eye-drop therapies, to improve corneal healing, maintain sustained nerve growth factor (NGF) expression, and reduce patient treatment burden. Redosable eye-drop gene therapy refers to a therapeutic approach that delivers genes encoding NGF directly to the cornea, enabling prolonged NGF production and supporting nerve regeneration over time. For instance, in July 2025, Krystal Biotech, a US-based biotechnology company, announced that the first patient was dosed in its Phase 1/2 EMERALD 1 study, a randomized, double-masked, placebo-controlled trial involving up to 27 adults with stage 2 or 3 neurotrophic keratitis. Designed to be administered twice weekly for eight weeks, KB801 aims to safely promote corneal healing while significantly reducing the treatment burden compared to existing six-times-a-day recombinant NGF eye drops.

What Are Latest Mergers And Acquisitions In The Neurotrophic Keratitis Treatment Market?

In October 2025, EyeDura Therapeutics, a US-based developer of sustained-release ophthalmic therapies, entered into a strategic research collaboration with the Singapore Eye Research Institute to accelerate the preclinical advancement of its insulin-based topical treatment for neurotrophic keratitis. With this collaboration, EyeDura aims to enhance technological capability and expedite clinical readiness by leveraging SERI’s specialized ophthalmic research infrastructure and preclinical disease models. The Singapore Eye Research Institute is a Singapore-based provider of advanced ophthalmic research, translational science expertise, and preclinical evaluation platforms for front-of-eye diseases.

Regional Outlook

North America was the largest region in the neurotrophic keratitis treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurotrophic Keratitis Treatment Market?

The neurotrophic keratitis treatment market consists of revenues earned by entities by providing services such as ophthalmic evaluation, prescription of medications, corneal neurotization, customized treatment plans, counseling and support, tarsorrhaphy and antibiotic medication supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurotrophic keratitis market also includes sales of artificial tears, recombinant human nerve growth factor eye drops, antibiotics and bandage contact lenses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurotrophic Keratitis Treatment Market Report 2026?

The neurotrophic keratitis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurotrophic keratitis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.